Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

RAB0521

Sigma-Aldrich

Bovine IL2 / Interleukin-2 ELISA Kit

for serum, plasma and cell culture supernatants

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

UNSPSC-Code:
41116158
NACRES:
NA.32

Speziesreaktivität

bovine

Verpackung

kit of 96 wells (12 strips x 8 wells)

Methode(n)

ELISA: suitable

Aufnahme

sample type serum
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <10%
intra-assay cv: <12%
sensitivity: 0.2 ng/mL

Nachweisverfahren

colorimetric

Versandbedingung

wet ice

Lagertemp.

−20°C

Angaben zum Gen

bovine ... IL2(280822)

Verwandte Kategorien

Allgemeine Beschreibung

This ELISA antibody pair detects bovine Interleukin-2.

Anwendung

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Sonstige Hinweise

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit-Komponenten auch einzeln erhältlich

Produkt-Nr.
Beschreibung
SDB
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDB
  • RABSTOP3ELISA Stop Solution (Item I)SDB
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDB
  • RABELADCELISA 1X Assay/Sample Diluent Buffer C (Item L)SDB
  • RABWASH420X Wash Buffer (Item B)SDB

Piktogramme

Corrosion
GHS05

Signalwort

Warning

H-Sätze

H290

P-Sätze

P234 - P390

Gefahreneinstufungen

Met. Corr. 1

Lagerklassenschlüssel

8A - Combustible corrosive hazardous materials

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Pratiksha Gulati et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(16), 3981-3993 (2018-05-12)
Purpose: Combination therapy of adoptively transferred redirected T cells and checkpoint inhibitors aims for higher response rates in tumors poorly responsive to immunotherapy like malignant pleural mesothelioma (MPM). Only most recently the issue of an optimally active chimeric antigen receptor
Tatsuo Matsuda et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 24(21), 5357-5367 (2018-05-04)
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anticancer cytotoxic T cells. Adoptive T-cell therapy with neoantigen-specific T-cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced
Francesco Nannini et al.
Scientific reports, 10(1), 19168-19168 (2020-11-07)
Antibody phage display is a powerful platform for discovery of clinically applicable high affinity monoclonal antibodies against a broad range of targets. Libraries generated from immunized animals offer the advantage of in vivo affinity-maturation of V regions prior to library
Liping Qiu et al.
Small (Weinheim an der Bergstrasse, Germany), 14(15), e1703539-e1703539 (2018-03-02)
The activation of tumor-specific effector immune cells is key for successful immunotherapy and vaccination is a powerful strategy to induce such adaptive immune responses. However, the generation of effective anticancer vaccines is challenging. To overcome these challenges, a novel straight-forward
Zhengping Hu et al.
Scientific reports, 8(1), 217-217 (2018-01-11)
The increased PD-L1 induces poorer prognosis in melanoma. The treatment with PD-1/PD-L1 antibodies have a low response rate. The combination immunotherapies are the encouraging drug development strategy to receive maximal therapeutic benefit. In this study, we investigated the enhanced antitumor
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.